In this respect, our finding on the role of ALOX15 as a potential therapeutic target of ischemia injury led to identification of daidzein as a potent ALOX15 inhibitor, which shows promise in the treatment for both phases of I/R injury. This evidence concerns the gene ALOX15 and ischemia.